NCT04083430View on ClinicalTrials.gov

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

February 15, 2025

Study Completion Date

December 15, 2025

Conditions
HealthyCytotoxicityYellow Fever Vaccination Reaction
Interventions
DRUG

Yellow Fever Vaccine

"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."

Trial Locations (1)

Unknown

Aarhus University Hospital, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER